Abilify in adolescents

Use of Abilify (aripiprazole) in adolescents aged 15 years and above with schizophrenia has been approved. The recommended dose in this population is 10mg daily. Use of the drug to treat manic episodes in bipolar disorder remains not recommended under 18 years.

View Abilify drug record

Further information: Otsuka


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Direct-acting oral anticoagulants set for wider use under NHS deal

Direct-acting oral anticoagulants set for wider use under NHS deal

More than half a million more people will be able to...

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...